Table 1.

Baseline characteristics and demographic data of studied groups.

Variable	Group 1 (Low-Dose Vitamin D) n = 58	Group 2 (High-Dose Vitamin D) n = 58	Significance p < 0.05
Age (mean ± SD)	65.7 ± 12.6	66.1 ± 11.2	p = 0.16
Male gender (n)	46	38	p = 0.07
Oxygenation (mean ± SD)
Oxygen saturation	88.3 ± 8.8	86.4 ± 13.4	p = 0.2
P/F ratio	197.3 ± 112.8	180.8 ± 99.7	p = 0.56
Respiratory rate	24.2 ± 4.4	25.9 ± 5.7	p = 0.21
Biochemical markers (mean ± SD)
Baseline C- reactive protein (CRP)	120.5 ± 100.4	145.5 ± 101.2	p = 0.18
Baseline interleukin-6 (IL-6)	15.7 ± 2.3	17.1 ± 1.6	p = 0.21
Baseline lactate dehydrogenase (LDH)	350.1 ± 140.6	360.6 ± 136.5	p = 0.72
Baseline D-Dimer	1.39 ± 1.8	1.1 ± 1.4	p = 0.29
Baseline ferritin	886.5 ± 87.2	704.1 ± 59.3	p = 0.17
Serum creatinine	1.26 ± 0.96	1.41 ± 0.59	p = 0.31
Total leucocytes count (TLC)	7.8 ± 3.6	8.2 ± 3.9	p = 0.60
Neutrophil lymphocytic ratio (NLR)	9.8 ± 8.8	7.2 ± 3.8	p = 0.06
Alanine transaminase (ALT)	52.1 ± 6.7	41.6 ± 3.2	p = 0.29
Aspartate transaminase (AST)	52.6 ± 4.3	45.2 ± 3.1	p = 0.28
Comorbidities (n)
Hypertension	31	31	p = 0.57
Diabetes	22	23	p = 0.6
Heart failure	0	2	p = 0.25
Chronic kidney disease	4	0	p = 0.07
Chronic liver disease	2	0	p = 25
Ischemic heart disease	10	10	p = 0.6
Atrial fibrillation	4	0	p = 0.07
Asthma	0	2	p = 0.24
Chronic obstructive pulmonary disease	2	2	p = 0.67
Medications (n)
Hydroxychloroquine	10	12	p = 0.15
Remdesivir	50	58	p = 0.12
Lopinavir/ritonavir	15	21	p = 0.23
Ivermectin	15	13	p = 0.41
Infliximab	58	56	p = 0.828
Tocilizumab	46	50	p = 0.34

NIMV; non-invasive mechanical ventilator, MV; mechanical ventilator, SD; standard deviation, n; the number of cases within the group, (n); the number of patients.